GLSI Greenwich LifeSciences Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) February 14, 2024

 

Greenwich LifeSciences, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware		001-39555		20-5473709
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

 

3992 Bluebonnet Dr, Building 14

Stafford, TX 77477

(Address of principal executive offices, including ZIP code)

 

(832) 819-3232

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value		GLSI		The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 4.01 Changes in Registrant’s Certifying Accountant.

 

On February 14, 2024, the audit committee of the Board of Directors of Greenwich LifeSciences, Inc. (the “Company”) approved the dismissal of MaloneBailey LLP (“Malone”) as the Company’s independent registered public accounting firm and approved the engagement of RBSM LLP (“RBSM”) as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ended December 31, 2023. Accordingly, on February 15, 2024, Malone was informed that it would be dismissed as the Company’s independent registered public accounting firm, effective immediately.

 

The report of Malone on the Company’s financial statements as of December 31, 2022 and 2021, and the related statements of operations, changes in stockholders’ equity and cash flows for the years ended December 31, 2021 and 2022 did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles.

 

During the fiscal years ended December 31, 2022 and 2021 there have been no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K), except for the material weaknesses in the Company’s internal control over financial reporting described in Part II, Item 9A, “Controls and Procedures,” in the Company’s annual reports on Form 10-K for the years ended December 31, 2022 and 2021, respectively and in Part I, Item 4, “Controls and Procedures,” in the Company’s quarterly reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023 filed with the SEC on May 22, 2023, August 21, 2023 and October 19, 2023, respectively. The Audit Committee has discussed the material weaknesses in the Company’s internal control over financial reporting with Malone and has authorized Malone to respond fully to the inquiries of RBSM, the Company’s new independent registered public accountants, concerning such weakness.

 

During the years ended December 31, 2023 and 2022 and through February 14, 2024, there were no disagreements between the Company and Malone on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Malone, would have caused it to make reference to the subject matter of the disagreement in connection with its report covering such period.

 

During the years ended December 31, 2023 and 2022 and through February 14, 2024, the date the audit committee of the Board approved the engagement of RBSM as the Company’s independent registered public accounting firm, neither the Company nor anyone on the Company’s behalf consulted with RBSM regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided to the Company by the Company that the Company concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement, as that term is described in Item 304(a)(1)(iv) of Regulation S-K under the Exchange Act, or a reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K under the Exchange Act.

 

The Company provided Malone with a copy of the foregoing disclosures prior to the filing of this Report and requested that Malone furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements made by the Company set forth above. A copy of Malone’s letter, dated February 16, 2024, is attached as Exhibit 16.1 to this Report.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

16.1	Letter from MaloneBailey LLP to the Securities and Exchange Commission dated February 16, 2024.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Greenwich LifeSciences, Inc.
Date: February 20, 2024	By:	/s/ Snehal Patel
		Snehal Patel
		Chief Executive Officer

 

 

Exhibit 16.1

 

 

February 16, 2024

 

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

We have read the statements under Item 4.01 of the Current Report on Form 8-K of Greenwich LifeSciences, Inc. to be filed with the Securities and Exchange Commission on or about February 20, 2024. We agree with all statements pertaining to us. We have no basis on which to agree or disagree with the other statements contained therein.

 

MaloneBailey, LLP

www.malonebailey.com

Houston, Texas

 

 

v3.24.0.1

Cover	Feb. 14, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Feb. 14, 2024
Entity File Number	001-39555
Entity Registrant Name	Greenwich LifeSciences, Inc.
Entity Central Index Key	0001799788
Entity Tax Identification Number	20-5473709
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3992 Bluebonnet Dr
Entity Address, Address Line Two	Building 14
Entity Address, City or Town	Stafford
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77477
City Area Code	(832)
Local Phone Number	819-3232
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	GLSI
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Information, Former Legal or Registered Name	Not Applicable

---